RADIOIMMUNOTHERAPY IN THE TREATMENT OF MALIGNANCIES
https://doi.org/10.21294/1814-4861-2016-15-2-101-106
Abstract
This review presents information about one of the promising areas of targeted therapy in modern oncology, which is called radioimmunotherapy. Particular attention is paid to the possibility of clinical application of this type of systemic treatment for patients with both hematologic malignancies and solid tumors.
About the Authors
V. I. Chernov
Tomsk Саnсеr Rеsеаrсh Institute, 5, Kooperativny Street, 634009-Tomsk, Russia;
National Research Tomsk Polytechnic University, 30, Lenina Avenue, 634009-Tomsk, Russia
Russian Federation
MD, DSc, Professor, Deputy Director for Science and Innovation, Head of Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 6301-3612.
Russian Federation
MD, DSc, Professor, Deputy Director for Science and Innovation, Head of Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 6301-3612.
O. D. Bragina
National Research Tomsk Polytechnic University, 30, Lenina Avenue, 634009-Tomsk, Russia
Russian Federation
MD, PhD, Researcher, National Research Polytechnic University (Tomsk, Russian Federation). SPIN-code: 7961-5918.
Russian Federation
MD, PhD, Researcher, National Research Polytechnic University (Tomsk, Russian Federation). SPIN-code: 7961-5918.
I. G. Sinilkin
Tomsk Саnсеr Rеsеаrсh Institute, 5, Kooperativny Street, 634009-Tomsk, Russia;
National Research Tomsk Polytechnic University, 30, Lenina Avenue, 634009-Tomsk, Russia
Russian Federation
MD, PhD, Senior Researcher, Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 7254-3474.
Russian Federation
MD, PhD, Senior Researcher, Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 7254-3474.
A. A. Titskaya
Tomsk Саnсеr Rеsеаrсh Institute, 5, Kooperativny Street, 634009-Tomsk, Russia;
National Research Tomsk Polytechnic University, 30, Lenina Avenue, 634009-Tomsk, Russia
Russian Federation
MD, PhD, Senior Researcher, Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 9110-1730.
Russian Federation
MD, PhD, Senior Researcher, Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 9110-1730.
R. V. Zelchan
Tomsk Саnсеr Rеsеаrсh Institute, 5, Kooperativny Street, 634009-Tomsk, Russia;
National Research Tomsk Polytechnic University, 30, Lenina Avenue, 634009-Tomsk, Russia
Russian Federation
MD, PhD, radiologist, Nuclear Medicine Department, Tomsk Cancer Research Institute, Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 2255-5282.
Russian Federation
MD, PhD, radiologist, Nuclear Medicine Department, Tomsk Cancer Research Institute, Nuclear Medicine Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-code: 2255-5282.
References
1. Gervas P.A., Litviakov N.V., Popova N.O., Dobrodeev A.Yu., Tarasova A.S., Yumov E.L., Ivanova F.G., Cheremisina O.V., Afanasyev S.G., Goldberg V.E., Cherdyntseva N.V. Problem and perspective to improve molecular testing to choose appropriate target therapy // Sibirskij onkologicheskij zhurnal. 2014. № 2. P. 46–55. [in Russian]
2. Imyanitov E.N. General principles of targeted therapy // Practical Oncology. 2010. Vol. 11 (3). P. 123–130. [in Russian]
3. Moiseenko V.M. Monoclononal antibody in treatment of malignancies // Practical oncology. 2003. Vol. 4 (3). P. 148–157. [in Russian]
4. Guidelines for chemotherapy of neoplastic diseases / Ed. by N.I. Perevodchikova. M., 2011. 518 p. [in Russian]
5. Practical recommendations for drug treatment of malignant tumors of the Russian Society of Clinical Oncology, 2014. [in Russian]
6. Clinical recommendation. Oncology / Ed. by V.I. Chissov, S.L. Daryalova. M., 2009. 925 p. [in Russian]
7. Abbas N., Heyerdahl H., Bruland O.S., Borrebæk J., Nesland J., Dahle J. Experimental a-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab // EJNMMI Res. 2011. Vol. 1 (1). P. 18. doi: 10.1186/2191-219X-1-18.
8. Akabani G., Carlin S., Welsh P., Zalutsky M.R. In vitro cytotoxicity of 211At labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction // Nucl. Med. Biol. 2006. Vol. 33 (3). P. 333–347.
9. Baechler S., Hobbs R.F., Jacene H.A., Bochud F.O., Wahl R.L., Sgouros G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab // J. Nucl. Med. 2010. Vol. 51 (12). P. 1878–1884. doi: 10.2967/jnumed.110.079947.
10. Behr T.M., Liersch T., Greiner-Bechert L., Griesinger F., Béhé M., Markus P.M., Gratz S., Angerstein C., Brittinger G., Becker H., Goldenberg D.M., Becker W. Radioimmunotherapy of Small Volume Disease of Metastatic Colorectal Cancer // Cancer. 2002. Vol. 94 (4 Suppl.). P. 1373–1381.
11. Behr T.M., Sharkey R.M., Juweid M.E., Dunn R.M., Vagg R.C., Ying Z., Zhang C.H., Swayne L.C., Vardi Y., Siegel J.A., Goldenberg D.M. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anticarcinoembryonic antigen murine monoclonal antibody IgG // J. Nucl. Med. 1997. Vol. 38 (6). P. 858–870.
12. Behr T.M., Salib A.L., Liersch T., Béhé M., Angerstein C., Blumenthal R.D., Fayyazi A., Sharkey R.M., Ringe B., Becker H., Wörmann B., Hiddemann W., Goldenberg D.M., Becker W. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: Preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study // Clin. Cancer. Res. 1999. Vol. 5 (10 Suppl.): 3232s-3242s.
13. Bertagnolli M.M. Radioimmunotherapy for Colorectal Cancer // Clin. Cancer. Res. 2005. Vol. 11 (13). P. 4637–4638.
14. Boerman O.C., Schaijk F.G., Oyen W.J., Corstens F.H. Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step // J. Nucl. Med. 2003. Vol. 44 (3). P. 400–411.
15. Chakraborti A.K., Garg S.K., Kumar R., Motiwala H.F., Jadhavar P.S. Progress in COX-2 inhibitors: a journey so far // Curr. Med. Chem. 2010. Vol. 17 (15). P. 1563–1593.
16. Chen K.T., Lee T.W., Lo J.M. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer // Nucl. Med. Biol. 2009. Vol. 36 (4). P. 355–361. doi: 10.1016/j.nucmedbio.2009.01.006.
17. Crow D.M., Williams L., Colcher D., Wong J.Y., Raubitschek A., Shively J.E. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and antiCEA antibodies with taxol // Bioconjug. Chem. 2005. Vol. 16 (5). P. 1117–1125.
18. Dadachova E., Casadevall A. Radiolabeled antibodies for therapy of infectious diseases // Microbiol. Spectr. 2014. Vol. 2 (6). doi: 10.1128/microbiolspec.AID-0023-2014.
19. Dewaraja Y.K., Schipper M.J., Roberson P.L., Wilderman S.J., Amro H., Regan D.D., Koral K.F., Kaminski M.S., Avram A.M. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results usin g3-dimensional dosimetry including radiobiologic modeling // J. Nucl. Med. 2010. Vol. 51 (7). P. 1155–1162. doi: 10.2967/jnumed.110.075176.
20. Divgi C.R., Scott A.M., Dantis L., Capitelli P., Siler K., Hilton S., Finn R.D., Kemeny N., Kelsen D., Kostakoglu L., Schiom J., Larson S.M. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma // J. Nucl. Med. 1995. Vol. 36 (4). P. 586–592.
21. Gregory S.A., Hohloch K., Gisselbrecht C., Tobinai K., Dreyling M. Harnessing the energy: development of radioimmunotherapy for patients with non Hodgkin’s lymphoma // Oncologist. 2009. Vol. 14 (Suppl 2). P. 4–16. doi: 10.1634/theoncologist.2009-S2-4.
22. Farrokhi S., Ravanbod M. R., Amiri S., Nabipour I., Assadi M. Radioimmunotherapy-based treatment of cancer // Iran J. Nucl. Med. 2012. Vol. 20 (1). С.45–53.
23. Jain M., Gupta S., Kaur S., Ponnusamy M.P., Batra S.K. Emerging Trends for Radioimmunotherapy in Solid Tumors // Cancer Biother. Radiopharm. 2013. Vol. 28 (9). P. 639–650. doi: 10.1089/cbr.2013.1523.
24. Hei T.K., Zhou H., Chai Y., Ponnaiya B., Ivanov V.N. Radiation induced non-targeted response: mechanism and potential clinical implications // Curr. Mol. Pharmacol. 2011. Vol. 4 (2). P. 96–105.
25. Kawashima H. Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies // Scientific World Journal. 2014. P. 1–10.
26. Kitson S.L., Cuccurullo V., Moody T.S., Mansi L. Radionuclide antibody-conjugates, a targeted therapy towards cancer // Curr. Radiopharm. 2013. Vol. 6 (2). P. 57–71.
27. Kohler G., Milstein C. Continious culture of fused cells secreting antibody of predefined specificity // Nature. 1975. Vol. 256 (5517). P. 495–497.
28. Lane D.M., Eagle K.F., Begent R.H., Hope-Stone L.D., Green A.J., Casey J.L., Keep P.A., Kelly A.M., Ledermann J.A., Glaser M.G. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab)2 antibodies // Br. J. Cancer. 1994. Vol. 70 (3). P. 521–525.
29. Liersch T., Meller J., Bittrich M., Kulle B., Becker H., Goldenberg D.M. Update of carcinoembryonic antigen radioimmunotherapy with (131) I-labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group // Ann. Surg. Oncol. 2007. Vol. 14 (9). P. 2577–2590.
30. Liersch T., Meller J., Kulle B., Behr T.M., Markus P., Langer C., Ghadimi B.M., Wegener W.A., Kovacs J., Horak I.D., Becker H., Goldenberg D.M. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results // J. Clin. Oncol. 2005. Vol. 23 (27). P. 6763–6770.
31. Meredith R.F., Buchsbaum D.J., Alvarez R.D., LoBuglio A.F. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer // Clin. Cancer Res. 2007. Vol. 13 (18 Pt 2): 5643s–5645s.
32. Meredith R.F., Khazaeli M.B., Macey D.J., Grizzle W.E., Mayo M., Schlom J., Russell C.D., LoBuglio A.F. Phase II study of interferonenhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer // Clin. Cancer Res. 1999. Vol. 5 (10 Suppl): 3254s–3258s.
33. Murray J.L., Macey D.J., Kasi L.P., Rieger P., Cunningham J., Bhadkamkar V., Zhang H.Z., Schlom J., Rosenblum M.G., Podoloff D.A. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer // Cancer. 1994. Vol. 73 (3 Suppl). P. 1057–1066.
34. Nicholson S., Gooden C.S., Hird V., Maraveyas A., Mason P., Lambert H.E., Meares C.F., Epenetos A.A. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis // Oncol. Rep. 1998. Vol. 5 (1). P. 223–266.
35. Palm S., Back T., Claesson I., Danielsson A., Elgqvist J., Frost S., Hultborn R., Jensen H., Lindegren S., Jacobsson L. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice // Int. J. Radiat. Oncol. Biol. Phys. 2007. Vol. 69 (2). P. 572–579.
36. Pouget J.P., Lozza1 C., Deshayes E., Boudousq V., Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy // Front. Med. (Lausanne). 2015. Vol. 2 (12). doi: 10.3389/fmed.2015.00012.
37. Rasaneh S., Rajabi H., Babaei M.H., Daha F.J. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer // Nucl. Med Biol. 2010. Vol. 37 (8). P. 949–955. doi: 10.1016/j.nucmedbio.2010.07.001.
38. Richman C.M., De Nardo S.J., O’Grady L.F., De Nardo G.L. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions // Cancer Res. 1995. Vol. 55 (23 Suppl.): 5916s–5920s.
39. Schrier D.M., Stemmer S.M., Johnson T., Kasliwal R., Lear J., Matthes S., Taffs S., Dufton C., Glenn S.D., Butchko G., Ceriani R., Rovira D., Bunn P., Shpall E.J., Bearman S.I., Purdy M., Cagnoni P., Jones R.B. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial // Cancer Res. 1995. Vol. 55 (23 Suppl.). P. 5921s–5924s.
40. Pandit-Taskar N., Jhaveri K., Divgi C. Radioimmunotherapy (RIT) of Cancer // Indian Journal of Nuclear Medicine. 2004. Vol. 19 (3). P. 53–67.
41. Taylor-Papadimitriou J., Burchell J., Miles D.W., Dalziel M. MUC1 and cancer Biochemical et Biophysical Acta (BBA) // Molecular Basis of Disease. 1999. Vol. 1455 (2–3). P. 301–313.
42. Tempero M., Leichner P., Baranowska-Kortylewicz J., Harrison K., Augustine S., Schlom J., Anderson J., Wisecarver J., Colcher D. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial // Clin. Cancer Res. 2000. Vol. 6 (8). P. 3095–3102.
43. Tomblyn M.B., Katin M.J., Wallner P.E. The New Golden Era for Radioimmunotherapy: Not Just for Lymphomas Anymore // Cancer Control. 2013. Vol. 20 (1). P. 60–71.
44. Wheeler R.H., Meredith R.F., Saleh M.N. A phase II trial of IL-1+ radioimmunotherapy (RIT) in patients with metastatic colon cancer // J. Clin. Oncol. 1994. Vol. 13. Abstract 959.
45. Schaefer N.G., Huang P., Buchanan J.W., Wahl R.L. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists // J. Nucl. Med. 2011. Vol. 52 (5). P. 830–838. doi: 10.2967/jnumed.110.085589.
46. Wang C.K. The progress of radiobiological models in modern radiotherapy with emphasis on the uncertain tissue // Mutat. Res. 2010. Vol. 704 (1–3). P. 175–181. doi: 10.1016/j.mrrev.2010.02.001.
Review
For citations:
Chernov V.I., Bragina O.D., Sinilkin I.G., Titskaya A.A., Zelchan R.V. RADIOIMMUNOTHERAPY IN THE TREATMENT OF MALIGNANCIES. Siberian journal of oncology. 2016;15(2):101-106. (In Russ.) https://doi.org/10.21294/1814-4861-2016-15-2-101-106
Views:
1272
Email this article 
